Ophthalmology Times: January 2022

The application of mitomycin C after corneal cross-linking does not prevent development of corneal haze after the procedure, but it does contribute to development of more corneal haze.

An evaluation conducted by the appropriate specialist is the most important factor in diagnosing and managing this patient population.

To control pain and inflammation most effectively and responsibly for our cataract surgery patients, we must not only use the appropriate drugs but also ensure they are delivered in the most beneficial manner. We should be mindful of the implications of our pharmaceutical strategies and their impact on our patients.